-
公开(公告)号：US20220348625A1
公开(公告)日：2022-11-03
申请号：US17663384
申请日：2022-05-13
IPC分类号： C07K14/55 , A61K47/65 , A61P37/04 , C07K14/715 , C07K16/28 , A61K38/17 , C12N15/62 , A61K38/20
摘要： Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
-
公开(公告)号：US11479538B2
公开(公告)日：2022-10-25
申请号：US16695239
申请日：2019-11-26
发明人： Saleem Ahmad
IPC分类号： C07D401/04 , C07D401/14 , C07D409/14 , C07D417/14 , A61K31/4439 , A61K45/06
摘要： The present invention provides compounds of Formula (I): a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US20220332817A1
公开(公告)日：2022-10-20
申请号：US17627085
申请日：2020-07-15
摘要： Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
公开(公告)号：US20220324836A1
公开(公告)日：2022-10-13
申请号：US17231088
申请日：2021-04-15
发明人： James A. Johnson , John Lloyd , Heather Finlay , James Neels , Naveen Kumar Dhondi , Prashantha Gunaga , Abhisek Banerjee , Ashokkumar Adisechan
IPC分类号： C07D401/14 , C07D239/95 , C07D401/12 , C07D403/04 , C07D403/12 , C07D407/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/517 , A61K31/5377 , A61K31/549 , A61K45/06 , C07D239/94 , C07D405/12 , C07D471/04 , C07D513/04
摘要： A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
-
公开(公告)号：US20220315569A1
公开(公告)日：2022-10-06
申请号：US17836596
申请日：2022-06-09
IPC分类号： C07D413/10 , C07D239/54 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D413/06 , C07D417/06 , C07D417/14
摘要： The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
-
公开(公告)号：US20220298186A1
公开(公告)日：2022-09-22
申请号：US17616748
申请日：2020-06-16
IPC分类号： C07F9/6558 , C07F9/59
摘要： The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
-
公开(公告)号：US11447775B2
公开(公告)日：2022-09-20
申请号：US16961624
申请日：2019-01-11
发明人： Richard E. Olson , Angela M. Cacace , Jere E. Meredith, Jr. , Nino Devidze , James K. Loy , Carl J. Baldick , Annapurna Pendri , Ivar M. McDonald , Peter Hagedorn , Marianne Lerbech Jensen
IPC分类号： C07H21/04 , C12N15/113
摘要： The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
-
公开(公告)号：US20220289739A1
公开(公告)日：2022-09-15
申请号：US17609443
申请日：2020-05-07
发明人： Alaric J. DYCKMAN , Laxman Pasunoori , Sreekantha Ratna Kumar , Srinivasan Kunchithaptham Duraisamy , Pitani Veera Venkata Srinivas , Vikram Bhogadi , Subramanya Hegde
IPC分类号： C07D471/04 , C07D519/00
摘要： Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
-
公开(公告)号：US20220281974A1
公开(公告)日：2022-09-08
申请号：US17701436
申请日：2022-03-22
发明人： Arvin YANG
IPC分类号： C07K16/28 , A61P35/00 , G01N33/574
摘要： The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
-
公开(公告)号：US20220275535A1
公开(公告)日：2022-09-01
申请号：US17673625
申请日：2022-02-16
发明人： Jonathan DAVIS , Dasa LIPOVSEK , Ray CAMPHAUSEN
摘要： Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
-
-
-
-
-
-
-
-
搜索结果
4587 条记录 (耗时 0.044 秒)
